Misplaced Pages

Taniborbactam

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 21:10, 24 December 2024 (Add: pmc, pmid, pages, issue, volume, journal, date, title, authors 1-17. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_toolbar). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 21:10, 24 December 2024 by Citation bot (talk | contribs) (Add: pmc, pmid, pages, issue, volume, journal, date, title, authors 1-17. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_toolbar)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Taniborbactam
Clinical data
Other namesVNRX-5133, VNRX5133
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (3R)-3-acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC19H28BN3O5
Molar mass389.26 g·mol
3D model (JSmol)
SMILES
  • B1((CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O

Taniborbactam (development code VNRX-5133) is a pharmaceutical drug that acts as a β-lactamase inhibitor. It inhibits the function of bacterial β-lactamases which impart resistance to β-lactam antibiotics. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the New Delhi metallo-beta-lactamase 1 group which are the most frequently identified sources of acquired antibiotic resistance worldwide.

Taniborbactam, in combination with cefepime, is in clinical trials for the treatment of bacterial infections, including urinary tract infection and pyelonephritis.

References

  1. Liu, Bin; Trout, Robert E. Lee; Chu, Guo-Hua; McGarry, Daniel; Jackson, Randy W.; Hamrick, Jodie C.; Daigle, Denis M.; Cusick, Susan M.; Pozzi, Cecilia; De Luca, Filomena; Benvenuti, Manuela; Mangani, Stefano; Docquier, Jean-Denis; Weiss, William J.; Pevear, Daniel C.; Xerri, Luigi; Burns, Christopher J. (2020). "Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections". Journal of Medicinal Chemistry. 63 (6): 2789–2801. doi:10.1021/acs.jmedchem.9b01518. PMC 7104248. PMID 31765155.
  2. Le Terrier, Christophe; Gruenig, Virginia; Fournier, Claudine; Nordmann, Patrice; Poirel, Laurent (2023). "NDM-9 resistance to taniborbactam". The Lancet Infectious Diseases. 23 (4): 401–402. doi:10.1016/S1473-3099(23)00069-5. PMID 36796395.
  3. Wagenlehner, Florian M.; Gasink, Leanne B.; McGovern, Paul C.; Moeck, Greg; McLeroth, Patrick; Dorr, Marybeth; Dane, Aaron; Henkel, Tim; CERTAIN-1 Study Team (2024). "Cefepime–Taniborbactam in Complicated Urinary Tract Infection". New England Journal of Medicine. 390 (7): 611–622. doi:10.1056/NEJMoa2304748. PMID 38354140.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  4. "Cefepime/taniborbactam - VenatoRx Pharmaceuticals". AdisInsight.
Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: